Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$250.6(0.2%)
Market Cap$32.2B
LTM Net Debt
($1,398.5M)
YoY Growth
N/A
3Y CAGR
+77.5%
5Y CAGR
+7.9%
Stock quality & Intrinsic value
5/10
61.9% overvalued
Alnylam Pharmaceuticals, Inc. Net Debt
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt | ($38.8M) | ($72.6M) | ($208.1M) | ($450.2M) | ($430.4M) | ($281.4M) | ($233.1M) | ($146.4M) | ($226.2M) | ($350.5M) | ($976.5M) | ($1,332.4M) | ($792.6M) | ($1,674.5M) | ($1,052.9M) | ($956.2M) | ($1,339.9M) | ($249.9M) | $420.1M | $243.2M |
Overvalued or undervalued?
Check the intrinsic value for ALNY
and see if it's the right time to invest.
Alnylam Pharmaceuticals, Inc. (ALNY) Net Debt comparison analysis
Crunching data... Almost there!
ALNY key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Alnylam Pharmaceuticals, Inc.'s Net Debt?
As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month Net Debt is ($1,398.5M), based on the financial report for Dec 31, 2024 (Q4 2024).
2) What is Alnylam Pharmaceuticals, Inc.'s Net Debt growth rate?
Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Debt growth was N/A. The average annual Net Debt growth rates for Alnylam Pharmaceuticals, Inc. have been 7.1% over the past three years, 7.9% over the past five years.